Diamyd Medical AB (publ) (DMYD-B.ST)
SEK 16.12
(2.54%)
SEK 16.12
(2.54%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 130 Thousand SEK | -76.19% |
| 2023 | 546 Thousand SEK | 20.26% |
| 2022 | 454 Thousand SEK | 79.45% |
| 2021 | 253 Thousand SEK | -25.81% |
| 2020 | 341 Thousand SEK | -78.25% |
| 2019 | 1.56 Million SEK | 115.98% |
| 2018 | 726 Thousand SEK | -21.26% |
| 2017 | 922 Thousand SEK | 21.8% |
| 2016 | 757 Thousand SEK | 47.56% |
| 2015 | 513 Thousand SEK | 15.8% |
| 2014 | 443 Thousand SEK | 343.0% |
| 2013 | 100 Thousand SEK | -90.72% |
| 2012 | 1.07 Million SEK | -99.62% |
| 2011 | 280.75 Million SEK | 148.39% |
| 2010 | 113.02 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | 18 Thousand SEK | -65.38% |
| 2024 Q3 | 52 Thousand SEK | 100.0% |
| 2024 Q2 | 26 Thousand SEK | -23.53% |
| 2024 Q1 | 34 Thousand SEK | -54.05% |
| 2023 Q1 | 211 Thousand SEK | 81.9% |
| 2023 FY | 546 Thousand SEK | 20.26% |
| 2023 Q4 | 74 Thousand SEK | -50.0% |
| 2023 Q3 | 148 Thousand SEK | 30.97% |
| 2023 Q2 | 113 Thousand SEK | -46.45% |
| 2022 Q4 | 116 Thousand SEK | -68.98% |
| 2022 FY | 454 Thousand SEK | 79.45% |
| 2022 Q3 | 374 Thousand SEK | 61.9% |
| 2022 Q2 | 231 Thousand SEK | 645.16% |
| 2022 Q1 | 31 Thousand SEK | -39.22% |
| 2021 Q1 | 81 Thousand SEK | 3.85% |
| 2021 Q2 | 1000.00 SEK | -98.77% |
| 2021 Q3 | 137 Thousand SEK | 13600.0% |
| 2021 FY | 253 Thousand SEK | -25.81% |
| 2021 Q4 | 51 Thousand SEK | -62.77% |
| 2020 Q1 | 118 Thousand SEK | -51.84% |
| 2020 Q3 | 97 Thousand SEK | 102.08% |
| 2020 Q4 | 78 Thousand SEK | -19.59% |
| 2020 Q2 | 48 Thousand SEK | -59.32% |
| 2020 FY | 341 Thousand SEK | -78.25% |
| 2019 Q4 | 245 Thousand SEK | -74.02% |
| 2019 Q1 | 261 Thousand SEK | 190.0% |
| 2019 FY | 1.56 Million SEK | 115.98% |
| 2019 Q2 | 97 Thousand SEK | -62.84% |
| 2019 Q3 | 943 Thousand SEK | 872.16% |
| 2018 Q3 | 34 Thousand SEK | 112.5% |
| 2018 FY | 726 Thousand SEK | -21.26% |
| 2018 Q4 | 90 Thousand SEK | 164.71% |
| 2018 Q2 | 16 Thousand SEK | -97.27% |
| 2018 Q1 | 586 Thousand SEK | 96.64% |
| 2017 FY | 922 Thousand SEK | 21.8% |
| 2017 Q4 | 298 Thousand SEK | 144.26% |
| 2017 Q1 | 437 Thousand SEK | 160.12% |
| 2017 Q2 | 47 Thousand SEK | -89.24% |
| 2017 Q3 | 122 Thousand SEK | 159.57% |
| 2016 FY | 757 Thousand SEK | 47.56% |
| 2016 Q1 | 190 Thousand SEK | 62.39% |
| 2016 Q2 | 287 Thousand SEK | 51.05% |
| 2016 Q3 | 112 Thousand SEK | -60.98% |
| 2016 Q4 | 168 Thousand SEK | 50.0% |
| 2015 Q4 | 117 Thousand SEK | -31.98% |
| 2015 Q3 | 172 Thousand SEK | 25.55% |
| 2015 Q2 | 137 Thousand SEK | 57.47% |
| 2015 Q1 | 87 Thousand SEK | -44.94% |
| 2015 FY | 513 Thousand SEK | 15.8% |
| 2014 Q4 | 158 Thousand SEK | 378.79% |
| 2014 Q2 | 81 Thousand SEK | -52.63% |
| 2014 Q3 | 33 Thousand SEK | -59.26% |
| 2014 Q1 | 171 Thousand SEK | 180.33% |
| 2014 FY | 443 Thousand SEK | 343.0% |
| 2013 Q1 | - SEK | -100.0% |
| 2013 Q4 | 61 Thousand SEK | 56.41% |
| 2013 FY | 100 Thousand SEK | -90.72% |
| 2013 Q3 | 39 Thousand SEK | 3800.0% |
| 2013 Q2 | 1000.00 SEK | 0.0% |
| 2012 Q1 | 54 Thousand SEK | -97.59% |
| 2012 Q4 | 94 Thousand SEK | -72.99% |
| 2012 Q2 | 582 Thousand SEK | 977.78% |
| 2012 Q3 | 348 Thousand SEK | -40.21% |
| 2012 FY | 1.07 Million SEK | -99.62% |
| 2011 Q1 | 144.47 Million SEK | 31.05% |
| 2011 FY | 280.75 Million SEK | 148.39% |
| 2011 Q2 | 114.51 Million SEK | -20.74% |
| 2011 Q3 | 19.52 Million SEK | -82.95% |
| 2011 Q4 | 2.24 Million SEK | -88.51% |
| 2010 Q2 | 164 Thousand SEK | 0.0% |
| 2010 FY | 113.02 Million SEK | 0.0% |
| 2010 Q3 | 1.33 Million SEK | 715.24% |
| 2010 Q4 | 110.24 Million SEK | 8145.47% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 99.776% |
| Ziccum AB (publ) | 3.74 Million SEK | 96.531% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.979% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 99.742% |
| Mendus AB (publ) | 28.48 Million SEK | 99.544% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.918% |
| Intervacc AB (publ) | 8.01 Million SEK | 98.378% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 97.028% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.924% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 99.704% |
| Aptahem AB (publ) | 2.63 Million SEK | 95.058% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | 87.44% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -68.831% |
| Fluicell AB (publ) | 3.33 Million SEK | 96.105% |
| Saniona AB (publ) | 16.84 Million SEK | 99.228% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 99.208% |
| Biovica International AB (publ) | 7.29 Million SEK | 98.217% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | 89.194% |
| AcouSort AB (publ) | 10.55 Million SEK | 98.768% |
| Xintela AB (publ) | 78 Thousand SEK | -66.667% |
| Abliva AB (publ) | 137 Thousand SEK | 5.109% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 99.774% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 93.545% |
| OncoZenge AB (publ) | 3000.00 SEK | -4233.333% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | 16.129% |
| CombiGene AB (publ) | 5.54 Million SEK | 97.655% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.989% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.992% |
| Corline Biomedical AB | 25.03 Million SEK | 99.481% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 97.71% |
| Isofol Medical AB (publ) | 721 Thousand SEK | 81.969% |
| I-Tech AB | 120.86 Million SEK | 99.892% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 99.903% |
| Cyxone AB (publ) | 5.14 Million SEK | 97.475% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 98.156% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 98.781% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 98.842% |
| Nanologica AB (publ) | 1.44 Million SEK | 90.991% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -145.283% |
| BioInvent International AB (publ) | 71.46 Million SEK | 99.818% |
| Alzinova AB (publ) | 270 Thousand SEK | 51.852% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 99.631% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 91.114% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 95.393% |
| Simris Alg AB (publ) | 4.35 Million SEK | 97.014% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.946% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -465.217% |